Aeglea BioTherapeutics, Inc. Profile Avatar - Palmy Investing

Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recomb…

Biotechnology
US, Austin [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Download
Cash Amount Pay Date
Download
Cash Amount Pay Date
End of AGLE's Analysis
CIK: 1636282 CUSIP: 00773J103 ISIN: US00773J2024 LEI: - UEI: -
Secondary Listings
AGLE has no secondary listings inside our databases.